Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion

Nektar Therapeutics (NASDAQ:NKTR) on Tuesday revealed topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin.The global Phase 2b study is being conducted in 92 patients with severe-to-very-severe alopecia areata.Alopecia areata is an autoimmune condition where the immune system attacks hair follicles, causing sudden, patchy hair loss, usually in coin-sized spots, but it can progress to total scalp (alopecia totalis) or body (alopecia ...